NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2022 · $208,265 — The global public health burden caused by SARS-CoV-2 and its resulting disease, COVID-19, has driven the rapid development of vaccines and treatment options. However, the continued emergence of novel SARS-CoV-2 variants of concern (VOC), which rapidly and globally replace earlier, previously predomi…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Noah M Merin · CEDARS-SINAI MEDICAL CENTER · 2022 · $402,829 — ABSTRACT Project 2 Project 2 of this U54 application is co-lead by Michael Karin (communicating PI) and Moshe Arditi (co-PI). This project will investigate the effect of pre-infection co-morbidities on the clinical outcome of SARS-Cov-2 infection. The novel severe acute respiratory syndrome coron…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Pamela J Bjorkman · ROCKEFELLER UNIVERSITY · 2022 · $1,507,637 — Project 3: Summary/Abstract SARS-CoV-2, a newly-emergent betacoronavirus in the sarbecovirus genus, resulted in a global pandemic in 2020, infecting millions and causing COVID-19 disease. Two other zoonotic betacoronaviruses, SARS-CoV (a sarbecovirus) and MERS-CoV (a merbecovirus), also resulted in …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Neil King · UNIVERSITY OF WASHINGTON · 2022 · $958,363 — PROJECT SUMMARY – CORE A: PROTEIN SCIENCES Core A (Protein Sciences) will provide essential support to our Projects and Cores in three areas: protein production and characterization, high-resolution structure determination, and process development and technology transfer. Core A’s protein production…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
David Veesler · UNIVERSITY OF WASHINGTON · 2022 · $881,853 — PROJECT SUMMARY – PROJECT 1: Definition of the structural principles underlying broadly protective humoral immunity Although the COVID-19 pandemic has accelerated the development of SARS-CoV-2 vaccines at an unprecedented pace, no licensed vaccines elicit broad protection against a large spectrum of…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Michael R. Farzan · SCRIPPS RESEARCH INSTITUTE, THE · 2022 · $1,876,244 — SUMMARY Coronaviruses, including SARS-CoV-2, pose obvious and imminent dangers to public health. This CAMPP proposal develops compounds that target multiple coronaviruses proteins and replication processes. These proteins include well established drug targets such as protease (Project 1) and replica…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Sanghyun Lee · BROWN UNIVERSITY · 2022 · $198,702 — Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19). Spike protein is the primary antigenic target for COVID vaccines and interfering with the interface between RBD (Receptor Binding Domain) of spike and ACE2 is the mechanism of …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
MING LUO · UNIVERSITY OF MINNESOTA · 2022 · $8,177,132 — Project 1 – Small Molecule Entry Inhibitors of Pandemic Viruses ABSTRACT Coronaviruses (CoVs), arenaviruses (Arv), flaviviruses (FLAVs) and filoviruses (FiVs) are enveloped viruses. During virus entry, receptor binding and refolding of the fusion protein, followed by lipid mixing, are three essenti…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
HANJOON RYU · 2022 · $4,158,139 — Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Kerry L Burnstein · MIAMI VA HEALTH CARE SYSTEM · 2022 — COVID-19 poses a tremendous health threat, particularly to individuals overrepresented in the US Veteran community. COVID-19 mortality is greater in men than in women; while this disparity is at least partially due to factors such as higher rates of smoking, a hormonal link is likely and can be rapi…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Tyler Nelson Starr · FRED HUTCHINSON CANCER CENTER · 2022 · $128,574 — PROJECT SUMMARY SARS-related coronaviruses (also known as sarbecoviruses) circulate in bat reservoirs, but two human spillovers in the past 20 years—SARS-CoV-1 in 2002 and SARS-CoV-2 in 2019—have caused globally devastating outbreaks. The emergence of SARS-CoV-2 from a previously unknown bat lineage…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Wah Chiu · STANFORD UNIVERSITY · 2022 · $165,085 — Herpesviruses are pathogens of medical and economic significance that cause a range of diseases in humans and animals. Varicella-zoster virus (VZV) is an important human alpha herpesvirus that causes varicella and zoster after reactivation from latency in sensory ganglia. The morphogenesis of varice…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
John R Cirrito · WASHINGTON UNIVERSITY · 2022 · $444,332 — ABSTRACT/PROJECT SUMMARY Coronavirus 2019 (COVID-19) has afflicted 6.2 million Americans and killed 190,000 as of early September 2020 (WHO website); a roughly 3% mortality. Between a shortage in testing and unidentified asymptomatic individuals, the actual number of those infected could be 6 to 24…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Matthew Reed Steinhart · INDIANA UNIVERSITY INDIANAPOLIS · 2022 · $51,752 — ABSTRACT Neurofibromatosis Type 2 (NF2) is a genetic condition in which specific types of tumors form in various locations throughout the body. Though the majority of these tumors grow slowly, the location of certain tumors can cause significant dysfunction. One of these tumor types grows on the ves…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Suzie H. Pun · UNIVERSITY OF WASHINGTON · 2022 · $455,938 — PROJECT SUMMARY The SARS-CoV-2 coronavirus, the cause of the COVID-19 global pandemic, is efficiently spread and has reached over 27 million confirmed cases as of September 8, 2020. There is therefore an urgent need for new technologies that can provide early detection of virus, reducing the transmi…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Mahesh B Chandrasekharan · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $190,625 — Project summary: ChIP-seq has enabled the mapping of genomic occupancy of many chromatin factors and epigenetic histone modifications, linked to normal growth and development and to the pathogenesis of many human diseases. ChIP-seq can also measure changes in the occupancy levels of epigenomic marks…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Rebecca Michelle DuBois · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2022 · $350,421 — PROJECT SUMMARY Human astroviruses (HAstV) are a leading cause of viral diarrhea in children. Divergent HAstV strains are associated with fatal human encephalitis. Currently, no vaccines or antiviral therapies exist for HAstV infections. Our goal is to identify sites of vulnerability (Achilles' heel…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
Bidadi Venkataram Prasad · BAYLOR COLLEGE OF MEDICINE · 2022 · $642,137 — The long-term goal of our research is to understand the structural basis of the complex processes that regulate the replication cycle of rotaviruses (RVs), which are the global pathogens causing life-threatening infantile gastroenteritis. During 2013-2016, our studies have answered several questions…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
John D Mountz · BIRMINGHAM VA MEDICAL CENTER · 2022 — The COVID-19 caused by the SARS-CoV-2 coronavirus infection is currently a global pandemic. The most important question is why some individuals produce rapid protective antibodies (Abs) and exhibit null or only mild symptoms, whereas others do not? A second urgent question is if a standard laborator…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2022
David Scott Wilson · JOHNS HOPKINS UNIVERSITY · 2022 · $204,688 — 1. ABSTRACT/SUMMARY Given that the site of entry of SARS-CoV-2 is the respiratory mucosa, an effective vaccine for SARS-CoV-2 should initiate both humoral and respiratory mucosal immune responses. Although an intranasal subunit vaccine would be an ideal platform for SARS-CoV-2, transport across the …